In an adult patient without known drug allergies or renal/hepatic impairment, which antibiotics provide coverage against gram‑negative bacteria?

Which Antibiotics Cover Gram-Negative Bacteria

For gram-negative coverage in adults without contraindications, use beta-lactams as your primary agents: ceftriaxone or cefotaxime for community-acquired infections, piperacillin-tazobactam for severe or hospital-acquired infections, and reserve carbapenems (meropenem) for multidrug-resistant organisms or critically ill patients.

Algorithmic Approach to Gram-Negative Coverage

First-Line Agents by Clinical Scenario

Mild to Moderate Community-Acquired Infections:

• Amoxicillin-clavulanic acid provides adequate gram-negative coverage for non-severe infections 1
• Ceftriaxone or cefotaxime offer broader gram-negative spectrum when beta-lactam/beta-lactamase inhibitor combinations are insufficient 1
• Fluoroquinolones (ciprofloxacin, levofloxacin) are second-choice options due to resistance concerns and should be restricted 1, 2

Severe or Hospital-Acquired Infections:

• Piperacillin-tazobactam is the preferred broad-spectrum agent for severe gram-negative infections 1
• Provides 84% coverage against gram-negative organisms in septic patients 3
• Ceftriaxone or cefotaxime remain viable alternatives for severe infections when combined with appropriate adjunctive therapy 1

Critically Ill or Multidrug-Resistant Concerns:

• Meropenem is the carbapenem of choice when resistance patterns or severity warrant escalation 1, 4
• Reserve for carbapenem-resistant organisms or empiric therapy in critically ill patients with risk factors for MDR pathogens 1

Combination Therapy Considerations

When double gram-negative coverage is needed:

• Piperacillin-tazobactam + gentamicin provides superior coverage compared to piperacillin-tazobactam alone (13% additional coverage) 3
• Aminoglycosides (gentamicin, tobramycin) add meaningful coverage when combined with beta-lactams, particularly for severe infections 1, 3
• Levofloxacin adds minimal benefit (only 8% additional coverage) when combined with piperacillin-tazobactam and provides no additional coverage with cefepime or meropenem 3

Specific Gram-Negative Organisms

Extended-Spectrum Beta-Lactamase (ESBL) Producers:

• Carbapenems remain gold standard, but carbapenem-sparing options exist for non-severe infections 4
• Piperacillin-tazobactam, cefepime, or fluoroquinolones may be used for mild-moderate infections if susceptible 2

Carbapenem-Resistant Enterobacterales (CRE):

• Newer beta-lactam/beta-lactamase inhibitor combinations: ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam 5, 6
• Cefiderocol as alternative 5, 6
• Colistin, polymyxin B, or aminoglycosides for limited options 2

Multidrug-Resistant Pseudomonas:

• Ceftazidime, cefepime, piperacillin-tazobactam, or carbapenems based on susceptibilities 2
• Ceftolozane-tazobactam or ceftazidime-avibactam for resistant strains 5, 6, 2

Carbapenem-Resistant Acinetobacter baumannii (CRAB):

• Colistin-based regimens, though combination therapy shows conflicting evidence over monotherapy 4
• Ampicillin-sulbactam if susceptible 4

Critical Pitfalls to Avoid

Fluoroquinolone Overuse: Despite historical popularity, fluoroquinolones should be restricted to second-line therapy due to increasing resistance rates and limited additional coverage when combined with broad-spectrum beta-lactams 1, 3, 2.

Inappropriate Carbapenem Use: While carbapenems provide excellent gram-negative coverage, their overuse drives resistance. Use carbapenem-sparing regimens for non-severe infections and low-risk sources when feasible 4.

Monotherapy in Severe Sepsis: For critically ill patients with gram-negative sepsis, consider combination therapy with an aminoglycoside to maximize coverage, particularly when piperacillin-tazobactam is the primary agent 3.

Neglecting Local Antibiograms: Susceptibility patterns vary significantly by institution. The 84% susceptibility to piperacillin-tazobactam noted in one study 3 may not reflect your local epidemiology—always consult institutional resistance data.

Antibiotic Stewardship Framework

The WHO AWaRe classification guides appropriate selection 1:

• Access antibiotics (amoxicillin-clavulanic acid, ampicillin, gentamicin, metronidazole): First-line for mild-moderate infections
• Watch antibiotics (ceftriaxone, cefotaxime, ciprofloxacin, piperacillin-tazobactam, meropenem): Reserved for severe infections or when Access agents fail

Optimize dosing based on pathogen MICs and use therapeutic drug monitoring when available, particularly for aminoglycosides and beta-lactams in critically ill patients 4.